Most postoperative chemotherapy regimens for fallopian tube cancer use a combination of platinum and paclitaxel-based regimens. Postoperative chemotherapy for fallopian tube cancer can prevent tumor recurrence and also kill tumors that cannot be completely removed by surgery. Clinically, the combination of platinum-based (such as cisplatin, carboplatin, etc.) and paclitaxel-based chemotherapy is mostly adopted as the postoperative chemotherapy regimen for fallopian tube cancer. This chemotherapy regimen is not suitable for patients with malignant disease, active infection or bleeding, and severe cardiopulmonary insufficiency. Postoperative chemotherapy for patients with fallopian tube cancer needs to ensure that organ function can tolerate chemotherapy, and various complications such as nausea, vomiting, anemia, bone marrow suppression, liver function impairment and so on may occur in the course of chemotherapy. The specific program of postoperative chemotherapy for fallopian tube cancer should be carried out under the guidance of doctors, and should not be used arbitrarily on its own, so as to avoid improper use of medication, adverse effects and delayed condition.